Staidson (Beijing) Biopharmaceuticals Co Ltd. and Pivotal S.L., full-service contract research organization (CRO), have announced a new strategic collaboration to assess Staidson´s investigational product BDB-001, a monoclonal anti-C5a antibody, in a clinical trial in Europe in progressive severe COVID-19 patients caused by SARS-CoV-2. The cumulative evidence to date, suggests that complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other immune-mediated diseases. Currently, seven coronavirus (CoVs) are known to cause human diseases: three of them, recognized as Severe Acute Respiratory Syndrome, SARS-CoV, Middle East Respiratory Syndrome, MERS-CoV, and SARS-CoV-2 (COVID-19) have led to more severe clinical outcomes for infected patients. A growing body of evidence indicates that SARS-CoV infection can over activate the complement cascade, thus affecting other organs and producing disease exacerbation.